BACKGROUND AND PURPOSEThe sympathetic nervous system regulates bone remodelling, in part, through ß 2 -adrenoceptor signalling. However, the physiological role of α 1 -adrenoceptor signalling in bone in vivo remains unclear. Therefore, to obtain a deeper understanding of bone remodelling by the sympathetic nervous system, we investigated the role of α 1B -adrenoceptor signalling in bone metabolism.
EXPERIMENTAL APPROACHPrazosin, a nonspecific α 1 -adrenoceptor antagonist, was administered for 2 weeks in C57BL6 mice, and efficacy was evaluated by bone microarchitecture using microcomputed tomography and determination of bone formation by fluorescent labelling of bone. We also compared the bone phenotype of α 1B -adrenoceptor null mice (α 1B À/À ) with that of wild-type littermates.
KEY RESULTSWe demonstrated that the systemic administration of prazosin decreased bone formation. In addition, α 1B -adrenoceptordeficient mice had a lower bone mass due to decreased bone formation but did not exhibit any changes in bone-resorbing activity. Furthermore, stimulation with phenylephrine, a non-specific α 1 -adrenoceptor agonist, increased the expression of the transcriptional factor CCAAT/enhancer-binding protein δ (Cebpd) in MC3T3-E1 osteoblastic cells. The overexpression of Cebpd induced cellular proliferation in MC3T3-E1 cells, whereas the silencing of Cebpd suppressed it.
CONCLUSIONS AND IMPLICATIONSTaken together, these results suggested that α 1B -adrenoceptor signalling is required for bone formation and regulated cellular proliferation through a mechanism relevant to the up-regulation of Cebpd in osteoblasts and, thus, provide new evidence for the physiological importance of α 1B -adrenoceptor signalling in bone homeostasis.
AbbreviationsBFR, bone formation rate; BMSC, bone marrow stromal cells; BV/TV, bone volume per total volume; Cebpd, CCAAT/enhancer-binding protein δ; Ctsk, cathepsin K; MAR, bone mineral apposition rate; MS/BS, mineral surface per bone surface; Nfatc1, nuclear factor of activated T-cells, cytoplasmic-1; Ob.N/BS, osteoblast number per bone surface; OC, osteocalcin; Oc.N/BS, osteoclast number per bone surface; Oc.S/BS, osteoclast surface per bone surface; Osx, osterix; RANKL, receptor activator of nuclear factor-kB ligand; Runx2, runt-related transcription factor